Cargando…

Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease

Light chain deposition disease (LCDD) is a rare systemic disorder caused by the deposition of light chain immunoglobulins, which often results in renal impairment associated with either nephrotic syndrome or asymptomatic proteinuria. B-cell neoplasms, such as multiple myeloma and lymphoproliferative...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Satoshi, Ohkawara, Hiroshi, Ogawa, Kazuei, Tanaka, Mizuko, Sano, Takahiro, Harada-Shirado, Kayo, Takahashi, Hiroshi, Ueda, Koki, Shichishima-Nakamura, Akiko, Matsumoto, Hayato, Ikeda, Kazuhiko, Kazama, Junichiro James, Hashimoto, Yuko, Ikezoe, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355407/
https://www.ncbi.nlm.nih.gov/pubmed/30101913
http://dx.doi.org/10.2169/internalmedicine.1018-18
_version_ 1783391326306304000
author Kimura, Satoshi
Ohkawara, Hiroshi
Ogawa, Kazuei
Tanaka, Mizuko
Sano, Takahiro
Harada-Shirado, Kayo
Takahashi, Hiroshi
Ueda, Koki
Shichishima-Nakamura, Akiko
Matsumoto, Hayato
Ikeda, Kazuhiko
Kazama, Junichiro James
Hashimoto, Yuko
Ikezoe, Takayuki
author_facet Kimura, Satoshi
Ohkawara, Hiroshi
Ogawa, Kazuei
Tanaka, Mizuko
Sano, Takahiro
Harada-Shirado, Kayo
Takahashi, Hiroshi
Ueda, Koki
Shichishima-Nakamura, Akiko
Matsumoto, Hayato
Ikeda, Kazuhiko
Kazama, Junichiro James
Hashimoto, Yuko
Ikezoe, Takayuki
author_sort Kimura, Satoshi
collection PubMed
description Light chain deposition disease (LCDD) is a rare systemic disorder caused by the deposition of light chain immunoglobulins, which often results in renal impairment associated with either nephrotic syndrome or asymptomatic proteinuria. B-cell neoplasms, such as multiple myeloma and lymphoproliferative disorders, are well-known underlying diseases in LCDD. Some chemotherapy regimens have been reported, but both evidence-based treatment and management for LCDD have yet to be established. We herein report three cases of LCDD treated with lenalidomide-based therapy, resulting in hematologic responses accompanied by a significant reduction in proteinuria and improvement in the renal function. We recommend lenalidomide-based therapy for renal impairment caused by LCDD.
format Online
Article
Text
id pubmed-6355407
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-63554072019-02-01 Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease Kimura, Satoshi Ohkawara, Hiroshi Ogawa, Kazuei Tanaka, Mizuko Sano, Takahiro Harada-Shirado, Kayo Takahashi, Hiroshi Ueda, Koki Shichishima-Nakamura, Akiko Matsumoto, Hayato Ikeda, Kazuhiko Kazama, Junichiro James Hashimoto, Yuko Ikezoe, Takayuki Intern Med Case Report Light chain deposition disease (LCDD) is a rare systemic disorder caused by the deposition of light chain immunoglobulins, which often results in renal impairment associated with either nephrotic syndrome or asymptomatic proteinuria. B-cell neoplasms, such as multiple myeloma and lymphoproliferative disorders, are well-known underlying diseases in LCDD. Some chemotherapy regimens have been reported, but both evidence-based treatment and management for LCDD have yet to be established. We herein report three cases of LCDD treated with lenalidomide-based therapy, resulting in hematologic responses accompanied by a significant reduction in proteinuria and improvement in the renal function. We recommend lenalidomide-based therapy for renal impairment caused by LCDD. The Japanese Society of Internal Medicine 2018-08-10 2018-12-15 /pmc/articles/PMC6355407/ /pubmed/30101913 http://dx.doi.org/10.2169/internalmedicine.1018-18 Text en Copyright © 2018 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Kimura, Satoshi
Ohkawara, Hiroshi
Ogawa, Kazuei
Tanaka, Mizuko
Sano, Takahiro
Harada-Shirado, Kayo
Takahashi, Hiroshi
Ueda, Koki
Shichishima-Nakamura, Akiko
Matsumoto, Hayato
Ikeda, Kazuhiko
Kazama, Junichiro James
Hashimoto, Yuko
Ikezoe, Takayuki
Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease
title Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease
title_full Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease
title_fullStr Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease
title_full_unstemmed Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease
title_short Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease
title_sort lenalidomide as a beneficial treatment option for renal impairment caused by light chain deposition disease
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355407/
https://www.ncbi.nlm.nih.gov/pubmed/30101913
http://dx.doi.org/10.2169/internalmedicine.1018-18
work_keys_str_mv AT kimurasatoshi lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease
AT ohkawarahiroshi lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease
AT ogawakazuei lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease
AT tanakamizuko lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease
AT sanotakahiro lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease
AT haradashiradokayo lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease
AT takahashihiroshi lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease
AT uedakoki lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease
AT shichishimanakamuraakiko lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease
AT matsumotohayato lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease
AT ikedakazuhiko lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease
AT kazamajunichirojames lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease
AT hashimotoyuko lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease
AT ikezoetakayuki lenalidomideasabeneficialtreatmentoptionforrenalimpairmentcausedbylightchaindepositiondisease